{"name":"Sawai Group Holdings","slug":"sawai","ticker":"4887.T","exchange":"TSE","domain":"sawaigroup.holdings","description":"Sawai Group Holdings Co., Ltd., together with subsidiaries, engages in the research and development, manufacture, and marketing of generic pharmaceuticals. The company offers generic drugs in various dosage forms, including tablets, oral dispersing tablets, capsules, granules, injectables, tapes, ophthalmic or nasal solutions, syrups, and other forms for various therapeutic areas comprising cardiovascular, gastro-intestinal, blood/body fluid, other metabolic, antibiotics, central nervous system, antiallergics, anti-cancer, urogenital organs and anus, chemotherapeutic and antineoplastic agents, respiratory system, etc., as well as vitamin preparations. It sells its generic drugs through distributors, wholesalers, and retailers in Japan and the United States. The company was founded in 1929 and is headquartered in Osaka, Japan.","hq":"Osaka, Japan","founded":1943,"employees":"3310","ceo":"Kazuhiko Sueyoshi","sector":"Generic Pharmaceuticals / Biosimilars","stockPrice":2082.5,"stockChange":2,"stockChangePercent":0.1,"marketCap":"$1.5B","metrics":{"revenue":1268673196.5720086,"revenueGrowth":1.2,"grossMargin":28.9,"rdSpend":0,"netIncome":61442271.45689979,"cash":294681406.76589936,"dividendYield":2.64,"peRatio":21.5,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Sawai's Generic Version of Losartan patent cliff ($100.0M at risk)","drug":"Sawai's Generic Version of Losartan","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-14","type":"earnings","headline":"Sawai Group Holdings Reports FY2023 Earnings","summary":"Sawai Group Holdings announced its FY2023 earnings, with revenue increasing by 10% year-over-year.","drugName":"","sentiment":"neutral"},{"date":"2023-08-01","type":"deal","headline":"Sawai Group Holdings Partners with Local Distributor","summary":"Sawai Group Holdings partnered with a local distributor to expand its product reach in the Japanese market.","drugName":"","sentiment":"positive"}],"realNews":[],"patents":[{"drugName":"Sawai's Generic Version of Losartan","drugSlug":"losartan","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":100000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Mitsubishi Tanabe Pharma","Takeda Pharmaceutical","Astellas Pharma"],"therapeuticFocus":["Cardiovascular","Neurology"],"financials":{"source":"yahoo_finance","revenue":1194985476.2208002,"revenuePeriod":"2025-03-31","revenueHistory":[{"period":"2025-03-31","value":1194985476.2208002},{"period":"2024-03-31","value":1118098872.6054},{"period":"2023-03-31","value":1034903041.0334},{"period":"2022-03-31","value":1225279885.4072}],"grossProfit":356250114.0384,"grossProfitHistory":[{"period":"2025-03-31","value":356250114.0384},{"period":"2024-03-31","value":343397748.8723},{"period":"2023-03-31","value":317686696.66840005},{"period":"2022-03-31","value":421365392.54840004}],"rdSpend":79611330.3181,"rdSpendHistory":[{"period":"2025-03-31","value":79611330.3181},{"period":"2024-03-31","value":77057294.1513},{"period":"2023-03-31","value":79080293.0953},{"period":"2022-03-31","value":154335853.81210002}],"sgaSpend":148677778.6406,"operatingIncome":131545506.33360001,"operatingIncomeHistory":[{"period":"2025-03-31","value":131545506.33360001},{"period":"2024-03-31","value":117706929.1823},{"period":"2023-03-31","value":101491328.27180001},{"period":"2022-03-31","value":-226879331.56960002}],"netIncome":145011093.0546,"netIncomeHistory":[{"period":"2025-03-31","value":145011093.0546},{"period":"2024-03-31","value":86578032.9315},{"period":"2023-03-31","value":80079148.8239},{"period":"2022-03-31","value":-178712991.0873}],"eps":184.45,"epsHistory":[{"period":"2025-03-31","value":184.45},{"period":"2024-03-31","value":103.93},{"period":"2023-03-31","value":96.2},{"period":"2022-03-31","value":-215.176667}],"cash":245193793.88450003,"cashHistory":[{"period":"2025-03-31","value":245193793.88450003},{"period":"2024-03-31","value":166695112.98560002},{"period":"2023-03-31","value":209102228.3492},{"period":"2022-03-31","value":301660751.9089}],"totalAssets":2241881107.8691,"totalLiabilities":1142798425.3373,"totalDebt":577433439.2063,"equity":1099082682.5318,"operatingCashflow":176070448.71670002,"operatingCashflowHistory":[{"period":"2025-03-31","value":176070448.71670002},{"period":"2024-03-31","value":146345007.9833},{"period":"2023-03-31","value":82348700.7642},{"period":"2022-03-31","value":216903418.027}],"capex":-173939977.95380002,"capexHistory":[{"period":"2025-03-31","value":-173939977.95380002},{"period":"2024-03-31","value":-155827815.5333},{"period":"2023-03-31","value":-171581919.8097},{"period":"2022-03-31","value":-147577772.9648}],"freeCashflow":2130470.7629,"dividendsPaid":-38373761.219000004,"buybacks":-210644765.044,"employees":3310,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":null,"ebit":null,"ebitda":null,"period":"2025-06-30","revenue":null,"epsBasic":42.36,"netIncome":null,"rdExpense":null,"epsDiluted":42.22,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":2082.5,"previousClose":2080.5,"fiftyTwoWeekHigh":2447,"fiftyTwoWeekLow":1689.5,"fiftyTwoWeekRange":"1689.5 - 2447.0","fiftyDayAverage":2174.79,"twoHundredDayAverage":2123.05,"beta":0.04,"enterpriseValue":1998614510.9814086,"forwardPE":12.2,"priceToBook":1.35,"priceToSales":1.2,"enterpriseToRevenue":1.57,"enterpriseToEbitda":10.21,"pegRatio":0,"ebitda":195813648.37140298,"ebitdaMargin":15.4,"freeCashflow":-6537605.521187527,"operatingCashflow":128258133.0496,"totalDebt":774353398.1320119,"debtToEquity":68.5,"currentRatio":2.25,"returnOnAssets":2.6,"returnOnEquity":-0.7,"analystRating":"","recommendationKey":"none","numberOfAnalysts":9,"targetMeanPrice":2716.67,"targetHighPrice":3300,"targetLowPrice":1850,"dividendRate":55,"payoutRatio":0.56,"fiveYearAvgDividendYield":0,"exDividendDate":1774828800,"insiderHeldPercent":7.5,"institutionHeldPercent":50.8,"sharesOutstanding":115485634,"floatShares":101224313,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":96.74,"epsForward":171.17,"revenuePerShare":1734.07,"bookValue":1548.24,"officers":[{"age":69,"name":"Mr. Mitsuo  Sawai","title":"Chairman, President, Group CEO & Group COO"},{"age":null,"name":"Jun  Tsujii","title":"General Manager of the Group Finance Department"},{"age":null,"name":"Mr. Yasushi  Kora","title":"General Manager of Public Relations & Investor Relations Office"},{"age":null,"name":"Hiroki  Tada","title":"Group Chief Marketing Officer"},{"age":null,"name":"Ichiro  Takahashi","title":"Group Chief Human Resource Officer, Group Chief General Affairs Officer & Chief Branding Officer"},{"age":66,"name":"Mr. Toru  Terashima","title":"Senior Executive Officer"},{"age":null,"name":"Mr. Toshiya  Hasuo","title":"Group Chief Production Officer"},{"age":null,"name":"Mr. Motohiko  Kimura","title":"Senior Managing Executive Officer"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.sawaigroup.holdings","phone":"81 6 6105 5818"}}